These effects were abolished completely by pharmacological inhibition of LPAR1 or siRNA-mediated silencing of DR6 expression (Fig. 3d, h), providing evidence for the involvement of the LPA-LPAR1-DR6 axis in increasing IL-10 secretion in melanoma. This evidence concerns the gene TNFRSF21 and melanoma.